Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...

An investigational oral fatty acid synthase (FASN) inhibitor was associated with significant improvements in metabolic ...

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge ...

A Pfizer Covid booster vaccination gave a fit 54-year-old chronic pain, NHS doctors found. Larry Lowe, from Omagh in Northern ...

With valuations growing across the stock market and the biopharma sector, it's only natural for value-sensitive investors to ...

Goldman Sachs senior biotechnology analyst in global investment research Chris Shibutani joins Market Domination Hosts Julie ...

Pfizer has announced the approval of HYMPAVZI by the US Food and Drug Administration (FDA) for patients with haemophilia A ...

Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly ...

In a previous interview, Lee hinted that a period of market volatility is expected, as 2024 heads for a soft landing.

The once-weekly injectable joins one-shot haemophilia B gene therapy Beqvez (fidanacogene elaparvovec) in Pfizer’s portfolio, ...

All the companies have skin in the game for clotting/bleeding disorders. The BMS-Pfizer Alliance market Factor Xa blood ...